Navigation Links
Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
Date:2/20/2008

nable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning improving our profitability, finding a financial partner for the depression indication, executing our plan to develop reimbursement coverage for depression, transferring the depression indication to a separate entity, maintaining at least a minority interest in such separate entity, seeking appropriate partnership opportunities, improving our cash position, enhancing the value of the company to shareholders, growing the company's business and continuing to strengthen the company's position in the neuromodulation device business sector. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquiries and any litigation relating thereto or to our stock option grants, procedures, and practices (includin
'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Cyberonics Licenses Obesity-Related Patents
2. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... On March 29, 2015 the United States celebrates ... all small business owners, for their commitment to their employees ... According to Zane Benefits' website, small businesses in the U.S. ... all jobs and employing over 60 million people. The 23 ... U.S. sales. The small business sector is growing rapidly, while ...
(Date:3/30/2015)... March 30, 2015 This report ... market over the forecast period of 2014 to ... a CAGR of 6.5% from 2014 to 2019. ... In this report, the global pharmacovigilance and drug ... segments on the basis of functionality, namely, adverse ...
(Date:3/30/2015)... 30, 2015 Recently, 10 Best Water ... Awards, with the top three winners being Fiji water, Tibet ... company’s website, along with other informative information about water. ... spring water, mineral water and sparkling water are among the ... the top exotic water brands highlighted on the site. ...
(Date:3/30/2015)... 2015 FMC Corporation’s Health and ... all current Epax® Ultra and Core concentrates manufactured ... The certification ensures the manufacturing process and all ... religious regulations for Halal. , The new ... to further advance its customer service to a ...
(Date:3/30/2015)... Slidezilla, an app from the makers of ... innovates the fun and simplicity of photo slideshows. The ... slideshows and then instantly share them across their Facebook, ... to create a slideshow app where users can share ... options to personalize them. You can choose your own ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Puts Spotlight on Small Businesses for National Mom and Pop Business Owners Day 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2
... it, some of us believe it but science is skeptical ... between faith, health and healing. ,Some scientists also ... worship, and service to others, influence our health. ,The ... well” but a “holistic approach to wellness”, which unites the ...
... role in increasing death risk.// It is the incidence of ... him. ,Depression had long been taken as a factor ... team of researchers from Washington University School of Medicine in ... the prime cause for such a case. ,A ...
... been found to reduce the risk of cellular ... top of standard immunosuppression. ,The drug, a ... receptor, thereby inhibiting T-cell proliferation. ,Patients who ... daclizumab or a placebo. ,The primary endpoint ...
... A study conducted in the Department of Medicine at ... // regular sunscreen routine in childhood can reduce the ... ,"Sunscreen has always been an important part of ... reduce the number of sunburns, especially for children," said ...
... suffering from congenital central hypoventilation syndrome (CCHS) may suffer ... ,Congenital Central Hypoventilation Syndrome is the absence ... time. Children suffering from CCHS may not breathe regularly ... may be able to breathe during wakeful hours but ...
... Income inequalities make dying also different by nature. Surprising, but ... exits between the near death conditions and the financial health ... 70 yrs may be 30% less likely than their poorer ... their deaths. They also may experience lower number of symptoms ...
Cached Medicine News:Health News:Link between Faith, Health and Healing 2Health News:Link between Faith, Health and Healing 3Health News:Use Of Sunscreen In Childhood And Prevents Future Skin Cancer 2
(Date:3/30/2015)... PLAINS, N.Y. , March 30, 2015  A ... new treatments for patients with a rare and lethal ... a recent licensing agreement with a new biotechnology company, ... been funding this work, led by Assistant Professor ... Cierpicki , Ph.D., at the University of Michigan, since ...
(Date:3/30/2015)... Perrigo Company plc (NYSE: PRGO ; TASE), a ... announced that it has completed the acquisition of Belgian-based ... equity transaction valued at approximately €3.8 billion, which includes ... Marc Coucke , Waterland Private Equity Fund V ... "The combination of Perrigo and Omega creates an ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... of the "Marine Biotechnology - Global Strategic ... Annual estimates and forecasts are provided for ... historic analysis is provided for these markets. Market ... secondary research. This report analyzes the ...
Breaking Medicine Technology:Leukemia Research Funded by The Leukemia & Lymphoma Society Gets Infusion of Support from Startup Biotechnology Company 2Leukemia Research Funded by The Leukemia & Lymphoma Society Gets Infusion of Support from Startup Biotechnology Company 3Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 2Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 3Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 4Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 5Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 2Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 3Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 4Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 5Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 6Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 7
... Repligen Corporation,(Nasdaq: RGEN ) announced today that ... to evaluate the use of RG1068, synthetic human ... by magnetic resonance,imaging (MRI). This Phase 3 study ... approximately 250 patients will receive an,unenhanced MRI followed ...
... First-in-Class Treatment for Type 2 Diabetes -, ... company focused on the discovery and development of,proprietary ... today that it has dosed the first cohort ... of MBX-2982, a potential first-in-class treatment,for type 2 ...
Cached Medicine Technology:Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 2Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 4Metabolex Initiates Phase 1 Trial of MBX-2982 2
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Conversion Kits For Modular Incubator Chamber...
Medicine Products: